Healthcare21 is delighted about the recently published clinical paper titled “Intravascular catheter migration: A cross-sectional and health-economic comparison of adhesive and subcutaneous engineered stabilisation devices for intravascular device securement,” by Dympna McParlan, et al., Belfast City Hospital, Belfast, Northern Ireland, which was published in the Journal of Vascular Access in June 2019.
The paper is a PICC securement study which compared one full year of Statlock use (1,111 patients) to one full year of SecurAcath Subcutaneous ESD (engineered stabilization device) use (1,139 patients). Average dwell time per patient was 6 months. There was a 5.9% catheter replacement rate with Statlock use compared to a 0% replacement with SecurAcath.
Cost savings due to decrease in catheter replacement was £17,952. Cost savings due to not changing out SecurAcath was £59,322 for a total savings of £77,274 annually.
McParlan states in the paper, “The introduction of subcutaneous ESDs has resulted in significant benefits for the patient, practitioner and the trust. This may have significant impact at a national level, indicating larger cost savings of over £8.8 million (€9.74/US$11.1 million) per year, simply by reducing catheter replacement from unintentional dislodgements and the frequent replacement of adhesive securements during each dressing change.”
For more information on the SecurAcath product, which is exclusively distributed in the UK by Healthcare21 / Aquilant, follow the link: https://www.aquilant.net/products/products_detail.asp?subp=products_by_all.asp&idProduct=12901.